http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2764243-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27d359af2c7cce97d2ef91579c9179ae |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 |
| filingDate | 2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e1bdaf69568a25ebf5c7b16c2d891fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e266cf3b1ebdc27ef795e851534d423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c57651b6b601bf3da7f68faafe272fe2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e00b7a9aa5bcf6139329112452b3a7c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5618b5d6602bfbd7b276e7bf0787286 |
| publicationDate | 2022-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2764243-C2 |
| titleOfInvention | Heterocyclic compounds as pad inhibitors |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to a compound by the formula (I), stereoisomers thereof and pharmaceutically acceptable salts thereof, wherein X represents O or S; Y is selected from O or N; Z is N; A represents CR 1 ; B represents CR 2 ; n equals 0 or 1; R 1 and R 2 are independently selected from hydrogen; R 3 is absent when Y is O or N when Y is selected from the group consisting of hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C(O)C 1-6 alkyl, SO 2 C 1-6 alkyl, SO 2 C 3-6 cycloalkyl and SO 2 C 6 aryl, wherein SO 2 C 6 aryl and SO 2 C 1-6 alkyl are optionally substituted with C 1-6 alkoxy, halogen and C 6 aryl; R 10 and R 11 are taken together, forming a 5-6-membered monocyclic saturated heterocyclic ring, wherein the 5-6-membered monocyclic saturated heterocyclic ring is optionally substituted with substituents selected from the group consisting of amino, C 1 alkylamino, and -NHC(O)CH=CHCH 2 N(CH 3 ) 2 ; R 12 , R 13 , R 14 , and R 15 are independently selected from the group consisting of hydrogen and C 1-6 alkyl, R 16 is selected from a 9-membered bicyclic heteroaryl containing 1 to 2 heteroatoms selected from N or S, wherein the 9-membered bicyclic heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-C 6 aryl, C 2-6 alkenyl-C 6 aryl, C 1-6 alkyl-C 3-5 heterocyclyl, wherein the heterocyclyl comprises one heteroatom selected from a nitrogen or oxygen atom (oxetan, tetrahydropyran, piperidine), C 3-5 heteroaryl, and C 1-6 alkyl-C 3-5 heteroaryl, wherein heteroaryl comprises from 1 to 2 heteroatoms in the ring, selected from a nitrogen or sulpur atom (pyridine, pyrimidine, pyridazine, and thiazole), and wherein C 1-6 alkyl, C 1-6 alkyl-C 6 aryl, C 3-5 heteroaryl, C 1-6 alkyl-C 3-5 heteroaryl, and C 1-6 alkyl-C 3-5 heterocyclyl are optionally substituted with one or several groups selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, halogen, hydroxyl, -CH 2 OH, and -COOH. The invention also relates to compounds by the formula (II) and compounds by the formula (III). n EFFECT: compounds represented by formulas (I), (II), (III) are intended for inhibiting the enzymatic activity of PAD4 in a cell; compound by the formula (I), formula (II), and formula (III) is intended for application for treating a PAD4-mediated condition selected from rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis. n n n n 19 cl, 1 tbl, 88 ex |
| priorityDate | 2017-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 637.